305 related articles for article (PubMed ID: 27461059)
1. Alteration of Esophageal Microbiome by Antibiotic Treatment Does Not Affect Incidence of Rat Esophageal Adenocarcinoma.
Sawada A; Fujiwara Y; Nagami Y; Tanaka F; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Watanabe T; Gi M; Wanibuchi H; Arakawa T
Dig Dis Sci; 2016 Nov; 61(11):3161-3168. PubMed ID: 27461059
[TBL] [Abstract][Full Text] [Related]
2. Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model.
Kohata Y; Nakahara K; Tanigawa T; Yamagami H; Shiba M; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
Dig Dis Sci; 2015 Sep; 60(9):2654-61. PubMed ID: 25862640
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma.
Snider EJ; Freedberg DE; Abrams JA
Dig Dis Sci; 2016 Aug; 61(8):2217-2225. PubMed ID: 27068172
[TBL] [Abstract][Full Text] [Related]
4. Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats.
Nishijima K; Miwa K; Miyashita T; Kinami S; Ninomiya I; Fushida S; Fujimura T; Hattori T
Ann Surg; 2004 Jul; 240(1):57-67. PubMed ID: 15213619
[TBL] [Abstract][Full Text] [Related]
5. High yield reproducible rat model recapitulating human Barrett's carcinogenesis.
Matsui D; Omstead AN; Kosovec JE; Komatsu Y; Lloyd EJ; Raphael H; Kelly RJ; Zaidi AH; Jobe BA
World J Gastroenterol; 2017 Sep; 23(33):6077-6087. PubMed ID: 28970723
[TBL] [Abstract][Full Text] [Related]
6. Influence of surgically induced gastric and gastroduodenal content reflux on esophageal carcinogenesis--experimental model in Wistar female rats.
Melo LL; Kruel CD; Kliemann LM; Cavazzola LT; Boeno Rda L; Silber PC; Grossi RS
Dis Esophagus; 1999; 12(2):106-15. PubMed ID: 10466042
[TBL] [Abstract][Full Text] [Related]
7. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
8. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens.
Sato T; Miwa K; Sahara H; Segawa M; Hattori T
Anticancer Res; 2002; 22(1A):39-44. PubMed ID: 12017320
[TBL] [Abstract][Full Text] [Related]
9. The Troublesome Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
Schneider JL; Corley DA
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):353-364. PubMed ID: 28577761
[TBL] [Abstract][Full Text] [Related]
10. Risk factors in the development of esophageal adenocarcinoma.
Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
[TBL] [Abstract][Full Text] [Related]
11. Etiology of Barrett's metaplasia and esophageal adenocarcinoma.
Kim R; Weissfeld JL; Reynolds JC; Kuller LH
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):369-77. PubMed ID: 9149898
[TBL] [Abstract][Full Text] [Related]
12. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
13. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
14. Screening for Barrett's esophagus.
Spechler SJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S25-9. PubMed ID: 12478241
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus and esophageal cancer after sleeve gastrectomy. Myth or reality?
Luna Aufroy A; Rebasa Cladera P; Montmany Vioque S
Cir Esp (Engl Ed); 2023 Oct; 101 Suppl 4():S39-S42. PubMed ID: 37979936
[TBL] [Abstract][Full Text] [Related]
16. Animal Model: Reflux Models in Esophageal Adenocarcinoma.
Masuda T; Mittal SK
Methods Mol Biol; 2018; 1756():143-150. PubMed ID: 29600367
[TBL] [Abstract][Full Text] [Related]
17. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.
Wennerström EC; Risques RA; Prunkard D; Giffen C; Corley DA; Murray LJ; Whiteman DC; Wu AH; Bernstein L; Ye W; Chow WH; Vaughan TL; Liao LM
Cancer Med; 2016 Sep; 5(9):2657-65. PubMed ID: 27384379
[TBL] [Abstract][Full Text] [Related]
19. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
[TBL] [Abstract][Full Text] [Related]
20. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
